ProPhase Labs Q2 FY26 net loss narrows to $3 million; revenue falls to $1 million

Reuters2026/08/19 20:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ProPhase Labs posted a GAAP net loss from continuing operations of USD 3 million, or USD 0.22 per share, for Q2 2026.
Net revenue slipped to USD 1 million from USD 1.2 million a year earlier, on lower supplements sales; no diagnostic-services revenue.
Gross margin narrowed to 22.4% from 58.9% in the year-ago quarter, reflecting consumer-products margin variability and product mix.
General and administration expense fell to USD 2.9 million from USD 4.6 million, driven by lower personnel, overhead, and professional fees.
Non-GAAP adjusted EBITDA from continuing operations improved to a loss of USD 561,000 from a loss of USD 807,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProPhase Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-039224), on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ProPhase Labs Q2 FY26 net loss narrows to $3 million; revenue falls to $1 million

You may also like

Crypto prices